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SHORT TITLE
SEXUAL IDENTIFICATION FROM BLOODSTAINS

ABSTRACT
The capabilities and the limitations involved in applying commercially prepared Radioimmunoassay (RIA) Kits,
for testosterone (T) and estrogen (E) , for the purpose of
identifying the sexual origin of a bloodstain were examined.
A total of forty whole blood samples were obtained from
equal numbers of young healthy male and female volunteers.
Bloodstains were prepared by absorbing these blood samples
onto 2 X 2 cm squares of white cotton linen. Two separate
studies were conducted using these stains. Both studies examined the fractional recovery of T and E when extracted
with diethyl ether, the ability of the RIA method to detect
T and E present in the extract at three bloodstain ages (2,
30, and 60 days after preparation) and whether a T:E ratio
could be utilized as a basis for discriminating between male
and female bloodstain samples.

The difference between the

studies lies in the prior knowledge of the sex of each individual blood sample.

In the first study the sex of each

blood sample was known,

(open study), whereas in the second

study the individual sex was not known but the number of
each sex was known (single-blind study).

A cross-reactivity

study was performed to determine the direct interference of
several commonly used synthetic steroids with the RIAs.

i

Significant amounts of T and E were detected in extracts of most bloodstains.

Both the open and single-

blind studies showed that there is a significant difference
between male and female T:E ratic:s 3nd that this difference
tends to diminish as the bloodstain age increases.

The

single blind study also showed this method to be at least
70% accurate when the bloodstain is 2 days old.

Cross-

reactivity studies showed only one of the synthetic steroids
tested reacted significantly with the estradiol antiserum.
All other tests showed no significant cross-reactivity of
the synthetic steroids tested with either the estradiol or
testosterone antiseras.

RIA of testosterone and estrogens

in bloodstains is of practical value in determining the
sexual origin of a bloodstain.

ii
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I.

INTRODUCTION

Forensic serology involves the examination of physical
evidence of a biological nature and includes the specialities of immunohemotology, biochemistry, enzymology and human genetics.

Most physical evidence examined by a forensic

serologist contains bloodstains of an unknown origin. Traditional approaches to the grouping of bloodstains involves
a comparison of the genetic markers found in a stain with
those of the suspect(s) and victim(s) involved in a crime.
Generally the information obtained from these genetic
markers which is useful for forensic purposes deals with
population frequency data.

Each antigen or isoenzyme de-

tected in a single bloodstain will decrease the possible
number of people that might have left a particular stain.
By using additional marker systems, the forensic scientist
can reduce that probable percentage dramatically.
In some instances, such as those crimes in which there
are no control bloodstains available for comparison, the
blood grouping data alone are of little value to the investigators.

It is occasionally possible, however, to obtain

additional information from the stain concerning some physical characteristics of the individual who left the stain.
The possibilities of discerning the race, age and sex
of the individual who left the stain are currently being

2
investigated (Brown, 1977; Garner, 1979 and Wigmore, 1979).
It is the determination of the sexual origin of a bloodstain through the quantification of
Testosterone (T)

t~e

sex hormones:

and Estrogens (E) by radioimmunoassay (RIA)

techniques, that will be the subject of this study.
This study will attempt to investigate three major
questions related to the RIA technique of determining the
sexual origin of a bloodstain.

The first question deals

with the feasibility of whether commercially available kits
are sensitive and selective enough to quantitate the amounts
of each steroid present in a specific area of bloodstained
material.

The quantities that are obtained will then be

calculated as a ratio of T:E and this final result will be
used as a basis for discriminating between male and female
samples in both open and blind studies.

Secondly, this

study will investigate the effect that the age of a bloodstain has on quantifying the steroids in stains up to 60
days old.

Finally, the question of whether synthetic

steroids, such as those used in oral contraceptive preparations, significantly cross-react in either RIA method
will be examined.
Testosterone and estrogen are well suited to indicate
sex based on the well established normal average values
for each in males and females between 15 and 45 years old.
According to the protocols contained in each RIA kit

1

-9

ng--nanogram (l0_ gram)
pg--picogram (10 12 gram)

(NEN,

3

1975, 1976) the normal ranges for testosterone in males and
1

females are 3-lOng /ml and 0-lng/ml plasma, respectively.
In a preliminary study only testosterone was assayed
in stains prepared from whole blood obtained from ten male
and six female volunteers.

Although the results from this

study demonstrated that sex determination is possible using only testosterone values, it also showed fluctuations
in values between individuals of the same sex as well as
some overlapping of values between sexes.

The concurrent

determination of total estrogens in a stain will hopefully
stabilize variation between individuals.

Also the use of

the two markers in a ratio form to indicate sex will eliminate the need to estimate the volume of blood in the stain
which is extracted in order to compare amounts per ml of
blood.

4

II.

LITERATURE REVIEW

Genetic markers currently employed in the forensic laboratory include the ABO, Rh and MN antigen-antibody systems,
the hemoglobin and haptoglobin polymorphic protein systems,
and the phosphoglucomutase (PGM) , adenylate kinase (AK) ,
erythrocytic acid phosphatase (EAP) , esterase D

(EsD~,

aden-

osine deaminase (ADA) , 6-phosphogluconate dehydrogenase (PGD)
and glucose-6-phosphate dehydrogenase (G-6-PD) polymorphic
enzyme systems (Culliford, 1971) .

These systems were cho-

sen for use in the examination of dried bloodstains because
they are:

1) genetically controlled; 2) present and de-

tectable in a bloodstain; and 3) supply individualizing information (Garner, 1979).
Research of constant interest in forensic serology is
the development of techniques which enable the researcher
to detect other marker systems present in a bloodstain.
Currently under investigation are the methods which detect
markers capable of supplying information about the race,
age and sex of the individual who left the stain.

Informa-

tion of this type is especially useful in cases where there
are no control samples available, which renders other blood
grouping data of little value (Wiqmore, 1979).

This in-

formation can, to a limited extent, inform police investigators about the characteristics of the suspect for whom
they are searching.

Information concerning the race and age characteristics is obtained through the detection of certain variants
in the hemoglobin system, which are present in a bloodstain
(Garner, 1979).

The techniques involved in this method

currently allows the forensic serologist to detect the presence of three hemoglobin variants:

HbS, HbC and HbF.

The

presence of HbS and HbC indicate the stain to be of Negroid
origin, whereas the presence of HbF indicates the blood to
be from an infant.
Determination of the sexual origin of a bloodstain became an active subject of research when Schwinger iri 1971
applied a fluorescent staining technique, which permits the
identification of the sex indicating Y-chromosomes in interphase and metaphase nuclei, to cell extracts from a bloodstain. Since this time several other studies have been published which have tested the accuracy or improved on the
method.

Aragones (1973) found there were many interfering

substances in the method used by Schwinger and he improved
upon the extraction to eliminate those interferences.

How-

ever, in studies which examine the accuracies of this method
in open and blind studies (Schwinger, 1973, and Wigmore,
1979) the method was found to be susceptible to erroneous
identifications, caused by interfering fluorescence and the
judgment of the observer.

This method has been reported to

be 40-80 % accurate in blind studies (Schwinger, 1973, and
Wigmore, 1979).

G
The development of radioimmunoassay (RIA)

techniques,

which are capable of detecting and quantifying small amounts
of specific substances, has provided the forensic serologist with a sensitive and accurate method for confirming
the presence of particular marker systems in a bloodstain.
With the recent development of new techniques for producing
highly specific antibodies against substances of interest
to the forensic serologist the RIA method has become a potentially powerful tool.
The application of RIA techniques for steroids in forensic serology was

~eported

independently by Brown (1976)

and Stuver (1976) at the 28th annual meeting of The American
Academy of Forensic Sciences.

In the next year at the 29th

annual meeting, Brown (1977) and Schehr (1977) independently announced the further application of steroid RIA techniques in bloodstains for the purpose of sex identification.
In the same year Moller (1977) published data on his application of RIA for detecting morphine in bloodstains.
Those four reports on the use of RIA for quantifying
the sex hormones:

testosterone, estrogen and progesterone,

in bloodstains for the purpose of sex identification, form
the basis of this study.

Although these three investi-

gators briefly reported on their efforts with this technique
there has, as yet, been no formal publication of their
methods and results.

Since the published data on the results

of RIA utilization for the purpose of identifying the sexual
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origin of bloodstains is liwited, i t is necessary to review
the literature dealing with the basic principles of the RIA
methodology and especially the specific techniques involved
in the RIA of steroids.
Although the methods involved in the RIA technique are
generally straightforward it is essential to have a clear
idea of the principles involved.
the RIA method is the antibody.

An essential component of

Antibodies were first recog-

nized by Von Behring (1890) when he determined that immunity
to diphtheria toxin was dependent upon the ability of a factor in the blood to inactivate the toxin.

He proved that

this factor resided in the serum and in 1901 he earned a
Nobel prize for his work with antiserum therapy.

Since that

time antibodies have been used clinically to neutralize biologic macromolecules and recently have been used diagnostically to measure concentrations of these macromolecules.
The clinical potential use of antibodies has been greatly
expanded with the production of antibodies which are directed
against small molecules of therapeutic and diagnostic interest, such as steroids, prostaglandins, thyroid hormones,
cyclic nucleotides and certain drugs (Ekins, 1974).
It is the discriminating ability of antibodies to recognize one particular material as distinct from any other which
is the basis for their use as an analytical tool in all immunologic methods.

Although there is a limitation on an anti-

body's ability to discriminate between similar structures
there are examples where extremely small alterations in the

8

structure of a molecule will drastically change its binding
to the antibody.

Antibodies are not usually preformed in

an individual but are produced in response to the entry of
the foreign material into the body.

Material that induces

an immunoresponse is called an immunogen.

The substance

that is bound by antibodies is called the antigen.

Most

substances are both immunogen and antigen, but these two
properties are distinct and not all antigens have the ability to initiate the formation of antibodies

(Thorell, 1978).

Antibodies comprise a group of related proteins in
blood plasma which are collectively referred to as immunoglobulins.

There are five known types of classes of imrnuno-

globulins:

IgG, IgM, IgA, IgD and IgE.

The basic structure

of all immunoglobulins is similar with a pair of large polypeptide chains (heavy chains, H), that consist of 446 amino
acids, each associated with a smaller chain (light chain, L)
214 aminoacids long (Roit, 1976).

The chains are arranged

in a Y-formation and are joined by disulfide bonds.

Each

immunoglobulin molecule has the ability to bind two antigen
molecules, one at each of the two binding sites, which are
located at the outer open end of each pair of H-L-chains.
Differences in the chemical composition of these two ends
of the molecules (the variable portions) are the structural
basis for the differences in the binding characteristics of
different antibodies.

The configuration of this binding

site can therefore assume such a variety of forms that it
very specifically fits to the surface of any antigenic

9

material.

The various types of iillP.lunoglobulins have some-

what different biologic functions.

IgG is the quantitative-

ly dominant immunoglobulin in plasma.

It is this class of

immunoglobulin that is usually utilized as the binder in
immunoassays (Thorell and Larson, 1978).
The antibodies produced in response to an immunogenic
stimulus constitute only a very small fraction of the total
antibody population occurring in the plasma of an animal.
In most assays, however, there is no need to isolate a particular fraction from the other antibodies present, since
the assay system only measures the binding of one particular radioactive antigen (Playfair, 1974).

Other antibodies

present will not interfere in this binding between the labeled antigen and its particular antibody.

These mutually

associated antigens and antibodies are called homologous
antigen and antibody.

In certain assay systems, one may

utilize antibody that is raised against a different immunogenr in this case the antigen and antibody are called
heterologous.
Radioimmunoassay (RIA) and related competitive proteinbinding methods began about 20 years ago as a cumbersome
research methodology in two specialist radioisotope centers
located in New York and London (Ekins, 1974).

These meth-

ods represent a common analytical approach of great sensitivity that has been applied to the measurement of more than
200 substances, many of which cannot be assayed by other
techniques.

It is essentially impossible to exaggerate the

10
diversity of applications for this methodology.

Virtually

every branch of medical and biological research has been
affected by these techniques.

In particular, endocrinology

has been greatly enriched by the new knowledge that has
come as a direct result of RIA methods.

These methodolo-

gies are being introduced into clinical medicine at a rapid
rate, and the growing commercial availability of radioassay
kits will revolutionize the routine practice of hospital
and research laboratories

(Challand, 1974).

The term radioimmunoassay was coined by Berson and
Yalow (1960) to describe their original methodology.

How-

ever, this term is . adequate for only a small portion of
related assays which are being used today.

There has been

an effort to select a descriptive word or phrase that would
be inclusive of all the various assay types, but it is now
felt that the proper individual terms be used for describing a particular assay (Ekins, 1974 and Thorell, 1978).
The term radioligand assay will be used interchangeably
with RIA.
In order to establish a radioligand assay, three prerequisites must be met:

(1) a receptor must be available

that specifically binds the ligand (antigen) to be measured;

(2) the ligand must be labeled with a radioactive

nuclide (radioligand); and (3) separation must be achievable between the ligand bound to the receptor and the ligand
that is unbound (Thorell, 1978).

The RIA generally consists
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of a competitive type radioligand assay, although a noncompetitive type is sometimes employed.
The competitive assay is the most common type of procedure used in RIA.

In this case, the . specific receptor

is an antibody directed against the ligand (antigen) to be
measured.

The ligand is injected into a species of animal

that sees this substance as foreign (iwmunogenic) and produces a specific antibody against the ligand.

The radio-

ligand is produced by coupling a radioactive nuclide to
the ligand as a marker so that the ligand can be measured.
The basic principle of RIA is the competition between the
radioactive and nonradioactive ligand for a fixed number
of antibody sites.

This interaction is represented sche-

matically in Figure 1.
If increasing amounts of nonradioactive ligand and a
fixed amount of radioactive ligand are allowed to react
with a constant amount of antibody, a decreasing amount of
radioactive ligand is bound to the antibody.

This can be

considered as a progressive dilution of radioligand bound
to the receptor, or as a progressive dilution of radioactive material with nonradioactive material, thereby reducing the specific activity of the ligand bound to the
receptor.
There is usually an incubation period for most assays,
during which time the binding reaction between receptor
anq ligand comes close to equilibrium.

This incubation va-

ries in time and temperature requiring anywhere from 30

Fig. 1 .

Labeled
Antigen
Ag*

Antibody-Antigen Interaction

Specific
Antibody
Ab

+

1

Labeled
Antigen*-Antibody
Complex
Ag*Ab

+

Unlabeled
Antigen
Ag

Unlabeled Antigen-Antibody
Complex
AgAb
1 From NEN Protocol, 1975.

ii\,;

Jj

minutes to 24 hours at 37°C to 4°C.

For most assays the

molar concentration of the receptor is chosen to be about
the same order of magnitude as the expected concentration
of the ligand in the unknown sample (Parker, 1976).

In

general, the more dilute the receptor, the more sensitive
the assay. At these low concentrations, longer incubation
times are necessary in order to achieve a sufficient interaction between ligand and receptor.
After the binding reaction is completed, the separation of free from antibody bound antigen must be achieved
in order to determine the partition of the radioactivity.
Various techniques have been employed for this purpose
(Radcliffe, 1974).

In many cases the antibody-antigen com-

plex is precipitated out of solution by the addition of a
saturated ammonium sulphate solution.

In some circum-

stances, a second incubation period is required, as in the
double antibody techniques.

When the antigen is a steroid,

separation is achieved through selective adsorption of the
free antigen onto dextran coated activated charcoal
(Kushinsky, 1975).

The amount of radioactivity of the

bound fraction is then determined.

There is an inverse

correlation between the amount of radioactivity bound and
the concentration of native ligand present in samples. This
relationship is usually not linear.

In order to be able

to measure the amount of ligand present in an unknown biologic sample, such as plasma or urine, the assay must include a standard series of tubes that contain known amounts,
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in sequential increments, of the substance to be assayed
(Bangham, 1974).

Based on the radioactivity bound to the

receptor in these standards, a standard curve is drawn
and the amount of unlabeled antigen in a sample can then
be determined by interpolation from this curve.
In the noncompetitive assay technique the antibody is
usually labeled instead of the ligand.

These methods are

particularly useful when the ligand cannot be labeled easily, as is the case with most viral antigens
1978).

(Thorell,

The receptor in this method is coupled to an in-

soluble, solid phase matrix.

An additional set of recep-

tors is labeled with radioactivity.

In the initial phase

the solid phase receptor is incubated with the sample containing the ligand to be measured until all ligand is bound
to this receptor.

The second step is to add the additional

set of radio-labeled receptors which are soluble.

This

radioreceptor will adhere to any bound ligand in the preparation.

The technique requires that the ligand be suf fi-

ciently large enough to have two or more molecular regions
that can act as combining sites (divalent or polyvalent).
After the second incubation the matrix is washed to remove
all nonbound radioactivity.

The remaining radioactivity

bound to the matrix is measured.

A standard curve is con-

structed by running a series of standards with known
cremental amounts of the ligand.

in-

The standard curve for

this assay is directly proportional to the concentration
of ligand present; that is, the larger the amount of ligand
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present, the larger the amount of radioactivity bound to
the matrix (Thorell, 1978).
RIA and related clinical methods derive their unique
usefulness from their very great sensitivity in relation to
other chemical techniques.

This sensitivity is related to

the extremely sensitive methods for the detection of radioactivity (Ekins, 1974).

It is possible to measure the ra-

.
t'ive iso
· t ope 125 I in
· quan t i' t 'ies as small as 10- 4 g (or
d ioac
approximately l0-

12

M) with good precision. Since the serum

concentrations of most hormones is on the order of 10-

9

to

10-lOM, detection of hormones at the lowest physiologic
concentration is now possible.

The quality of any assay

is determined by four factors:

sensitivity, specificity,

precision, and accuracy.

Specificity is predominantly a

property which is dependent on the receptor.

It is the

ability of the assay to measure one specific compound and
no other.

The specificity or lack of it is a major problem

in some assays.

For many biologically important compounds,

a number of compounds exist with similar chemical structures.

Steroid pormone assays are a prime example where

this problem occurs (James, 1974).

There are many steroid

derivatives with small differences in structure but with
marked physiologic differences.

In this situation there

are two means of enabling the accurate measurement of a
single steroid--the production and selection of highly specific antisera, which requires significant effort especially in the formation of a suitable immunogen.

However, this
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cannot be accomplished to the point of exclusion of similar
substances and therefore the situation is sometimes improved
by chemical separation to isolate the compound of interest
from the interfering substances.

Solvent extraction, wash-

ing procedures and various types of chromatography are the
procedures most often used (Thorell, 1974).
The sensitivity of an assay is limited by two factors:
the affinity of the receptor and the specific activity of
the radioligand.

The affinity of a receptor reflects the

energy in binding between the ligand and the receptor, the
firmness of the binding.

To be able to measure minute

amounts of hormones and other biologic compounds with adequate sensitivity the energy of binding has to be very high.
This often is the limiting factor for the sensitivity of an
RIA (Thorell, 1974).
The specific details involving the production of proper immunogens, specific antibodies, the preparation of the
radioactive ligands and the kinetics of the antibody-antigen interaction is beyond the scope of this review.

They

are clearly detailed in several excellent reviews on RIA
and related techniques (Ekins, 1974; Bangham, 1974; Hunter,
1974; Playfair, 1974; Parker, 1976; Dawson, 1978, and
Thorell, 1978).

Measurement of a substance by the RIA

technique depends on its ability to compete with a suitably
labeled compound for a binding site.

The nature and type

of radiolabel influences sensitivity of these assays.

The

14 C an d 3 H suita
. bl e as
.
. .
synt h esis
o f compoun d s containing
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markers in a RIA may be expensive, and in addition their
specific activity may be so low that undesirably large
amounts must be used, which will cause a decrease in the
sensitivity of the assay.

Manipulations involved in

3

H

.
an d 14c counting,
including sample preparation, quenching
corrections, disposal of organic solvents and other difficulties involved in liquid scintillation counting also make
use of these types of labels undesirable when alternatives
are available.

125

I and

131

I have been used for labeling

tyrosine conjugates of drugs and labeling of some steroids.
They not only produce labels of high specific activity but
permit the use of simpler counting methods

(Marks, 1974).

In pharmacology RIA offers a sensitive, precise and
specific method for measuring concentrations of drugs and
other significant substances in tissues and blood.

This

allows for research to be conducted into their distribution, metabolism and pharmacokinetics and, increasingly,
for monitoring drug therapy (Marks, 1974).

For many drugs

there is no other means available to permit accurate measurements under 9linical conditions, so that for even for
well established drugs such as morphine, virtually no information had been available concerning its concentration
in blood under optimum therapeutic conditions.

Radioimmuno-

assay techniques which have currently been developed are
helping to· eliminate this deficiency.
Although the major obstacle which researchers face in
their attempt to develop RIA for proteins and peptides is
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in the isolation of the pure compound, the main problem confronting those developing RIAs for drugs and steroids is in
the production of a suitable antisera.

These compounds are

rendered immunogenic by chemically coupling them to a larger
I

antigenic molecule.

This usually involves the formation of

a peptide bound between the drug or steroid and the protein,
usually but not always, bovine serum albumin (BSA).

The

point of conjugation often has an important influence on the
degree of specificity of the antibody produced; this is
especially true with steroids.

It has been only in the last

five years that highly specific, low cross-reacting, antibodies have been produced utilizing immunogens conjugated at
different points on the haptene molecule (Ekins, 1974).

An-

other difficulty encountered when dealing with these compounds is that most cannot be radioiodinated directly.
difficulty is overcome by the use of
drugs or steroids.
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c-

or

3

This

tt-labelled

Currently drugs or steroids are being

coupled to compounds containing a p-hydroxyphenyl group that
can be radioiodinated (Hunter, 1974).
As stated above a major problem with steroid RIA is
the cross-reactivity of related steroids with the antibodies
produced (James, 1974).

For example in the RIA of testos-

terone the major cross-reacting steroid is dihydrotestosterone which initially showed a 100% cross-reactivity with
antisera manufactured by New England Nuclear (NEN, 1975).
This cross-reactivity has recently been reduced to 56%
through production of antisera to a different conjugate.
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This problem is also evident in the RIA of the estrogens.
Here the three major estrogens:

estradiol, estrone and

estriol all cross-react significantly with antisera produced against an estradiol conjugate.

When dealing with

the measurement of these steroids, it is sometimes necessary, depending on the specificity required, to fractionate the sample extract by column chromatography prior to
the assay.

With increased antibody specificity the chroma-

tographic step can be eliminated (Castro, 1973; Stahl, 1975
and Sheldon, 1977) which is desirable when dealing with
small samples.
Many of the RIAs developed for pharmacology also have
a potential for use in the forensic sciences.

Those RIAs

developed for morphine and opiate alkaloids, lysergic acid
derivatives, tetrahydrocannabinol (cannabis), barbituates
and other drugs of abuse provide a screening method to detect the particular drug in a suspected abuser, in an overdose case or in blood samples found at a crime scene.
Blood or bloodstains are one of the most frequently
encountered types of evidence at crime scenes; especially
crimes of the

mo~t

serious nature such as homocides, as-

saults and rapes (Saferstein, 1977).

The determination of

other marker systems in these samples, such as sexual origin, will complement the evidence provided by the identification of the major blood factors.

As stated previously

the RIA method offers an accurate and sensitive method for
sex determination based on the quantity of testosterone and
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estrogens present in a quantity of bloodstained material.
Because the steroid molecule is highly stable (Morrison,
1973) it is capable of withstanding the effects of drying
in a bloodstain.

The proper preparation and extraction

of the stain with ether enables the investigator to measure each steroid fairly accurately. The results obtained
are then calculated as a ratio for each sample and used
as a basis for discriminating between male and female
samples.
When working with any RIA method it is essential to
know the limits of the antibody being employed, especially
in reference to its cross-reactivity with compounds other
than the one which is being measured.

In working with

blood it is not uncommon to have several compounds present
in the extract, and therefore in the test system, which are
capable of cross-reacting with the antibody and causing an
overestimation of the quantity of the compound being measured (James, 1974).

This would also be true when working

with bloodstains since diethylether will extract from a
bloodstain many _nf the organic soluble steroids present.
The cross-reactivity of many of the naturally

occurrin~

steroid hormones with the antisera used in this study has
been reported by the manufacturer, New England Nuclear
(protocols 1975, 1976).

However, the question of cross-

reactivity of this antisera with synthetic steroid hormanes, used in oral contraceptives, has not been reported
and is undertaken in this study.
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The compounds ethinyl estradiol (EE 2 ), ethynodial diacetate, mestranol, norethindrone (NET), norgestrel (Nor-G)
and norethylnodrel are the most commonly used synthetics
in oral contraceptive preparations

(Murad, 1975).

The

first and third are synthetic estrogens and the remaining
four are synthetic progestins.

Either group is capable of

cross-reacting with the antiserum used in either the testosterone or estrogen assays

(see Figures 2 and 2A) .

The literature available on these compounds is extensive and a good review of their metabolism has been published (Ranney, 1977).

EE 2 , NET and Nor-Gare the most

representative of this group since mestranol is converted
to EE 2 and the others to NET in vivo.

Reports concerning

the plasma concentration of these drugs after administration is limited.

This information is necessary in order

to perform significant studies dealing with cross-reactivity.

Verma (1975) reports the plasma levels to range from

144 to 248 pg/ml after 6 hours in women receiving 50ug of
EE 2 or mestranol, through the use of a competitive protein
binding

radioass~y

for EE 2 .

RIA procedures developed for

NET (Nygren, 19ii and St~nczyk, 1978) show plasma l~vels
to rise and fall rapidly and attain peak levels of approximately 15ng/ml within 1.5 hours after ingestion of a lmg
dose.

Finally, Brenner (1977) reported levels of Nor-G,

as determined by RIA, to range between 8-12ng/ml plasma in
women receiving 500ug per day for twenty-one days.

Fig. 2 Testosterone and Synthetic Progestins
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The normal daily dose for each of these compounds as
reported by Murad (1975) are as follows:

EE 2 : 20ug to

lOOug with an average of SOug; NET: 500ug to 10,000ug with
an average of l,OOOus; Nor-G: 75ug and 500ug.
In addition to their cross-reactivity potentials these
compounds could affect the assay in another way.

Briggs

(1976) has reported that the administration of these synthetic hormones cause changes in the estradiol fluctuations
seen in the female cycle.

In women being administered

these preparations there are no estradiol peaks observed,
due to LH suppression, although basal levels remain the
same.

These drugs affect progestrone levels in the same

manner.
slightly.

Testosterone levels have been observed to increase
In essence these drugs could cause an over or

underestimation of the actual T and/or E levels present in
a stain from a female who is taking such medication.
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III.

EXPERIMENTAL

During the course of the study blood samples were obtained from two groups of volunteers.

The first group of

twenty-four samples, obtained from twelve male and twelve
females, constituted an open study in which the sex of each
individual sample was known.

The second group of sixteen

samples, eight males and eight females, constituted a
single-blind study where the number of male and female
samples were known but the sex of each individual sample
was not known until all assays were completed.

The volun-

teers ranged in age between 18 and 27 years.
All blood samples were drawn by a qualified medical
technologist into 7ml EDTA vacutainer tubes to prevent coagulation.

From each individual blood sample twelve wh d le

bloodstains were prepared by absorbing O. lml of whole blood
onto 2X2cm square pieces of white cotton cloth and allowing them to dry completely on a large flat piece of clear
-~

glass.

Each gro-;p of stains was then stored in labeled

plastic bags.

Assays were run simultaneously for testos-

terone and estrogen at three different intervals from the
time of staining.

The first assay was performed 48-72

hours after the stains were made.

The second and third

assays were subsequently conducted at one and two month
intervals.
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The equipment, reagents and space required for the completion of this study were made available in the Department
of Pharmacology and Toxicology at the University of Rhode
Island.

Special chemicals such as BSA, Fr. IV; gamma glob-

ulin, Fr. II; norit A, neutral; and dextran T-70 were obtained from Sigma Chemical Company, St. Louis, Mo.
chemicals utilized were of reagent grade quality.

All
Anes-

thetic grade ether, used for extraction of the samples, was
obtained from the Department of Medicinal Chemistry at the
University of Rhode Island.

The pure synthetic steroids

used in the cross-reactivity studies were supplied courtesy
of Ortho Pharmaceutical Corporation, Raritan, N.J.

(Ethynyl

Estradiol, Mestranol and Norethindrone); Searle and Co.,
San Juan, Puerto Rico (Ethynodiol Diacetate and Norethynodrel); and lfyeth Laboratories, Inc., Philadelphia, Pa.
(Ethinyl Estradiol and dl-Norgestrel).
Commercial RIA kits for testosterone and estrogens,
sufficient for 500 tubes each, were obtained from New
England Nuclear Biomedical Assay Laboratories, North
Billerica, Mass.

Each RIA kit consists of five vials of

lyophilized antiserum, one vial each of tritium labeled
steroid in organic solvent and steroid standard in buffer
and a protocol which outlines the preparation of the components and the basics for their use in a RIA determination
in plasma or urine samples.

The methods described for this

study follow those outlined in the protocols with some modifications.
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The buffer and dextran coated charcoal systems used
in each assay were freshly prepared prior to each assay.
Their formulations are shown in Table 1.

Prior to the use

of the antisera in the RIA determinations they had to be
reconstituted with the respective assay buffer to obtain a
specific titer.

The following rapid procedure was used

for the titer determination and reconstitution of each
antiserum.
Five and 2.5mls of the proper assay buffer were added
to the lyophilized vials of testosterone and estradiol antisera, respectively.

The vials were gently inverted several

times over a 15-30 minute period to insure complete dissolution.

Fifty and 25% dilutions were prepared by adding

0.15 and 0.30ml of assay buffer to 0.15 and 0.10 ml aliquots of the concentrates.

Eight 12X75mm disposable glass

tubes were prepared in accordance with Table 2 for each
antiserum.

The tubes were mixed on a vortex genie and in-

cubated at 4°C for 24 hours.

They were then placed in an

ice bath and the proper cold dextran coated charcoal suspension (under constant stirring) was added to all except
tubes 1 and 2.

The tubes were allowed to stand, on ice,

for 5 minutes and then centrifuged under refrigeration at
2700 rpm for 30 minutes.

After centrifuging the tubes

were put on ice and 0.5ml of the supernatant was transferred into scintillation vials containing 10 ml of Hydromix

1

1 Hydromix is a trademarl< of Yorktown Research, Hackensack,,
NJ.
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Table I

Solutions for RIA

Testosterone System
Stock Solution

Charcoal Solution

13.Bg
NaH2P04·H20
2.0g
NaN3
Dissolve in 900ml of
distilled water.+
Adjust pH to 7.4-0.l
with lN NaOH then
q.s. to lOOOml with
distilled water.

NaCl
Dextran T-70
Norit A, neutral
Dissolve in lOOml of
stock solution.

0.900g
0.025g
0.250g

Assay Buffer
BSA Fr.V
5.0g
Stock solution
SOOml
Dilute to lOOOml
with distilled water.
Estrogen System
Assay Buffer

Charcoal Solution

5.38g
NaH2P04·H20
16.35g
Na2HP04·7H20
NaCl
9.00g
1. OOg
NaN3
ll-Globulin Fr.II
l.OOg
Dissolve in 900ml
of distilled water.
Adjust pH to 7.0~0.l
with lN NaOH then
q.s. to lOOOml with
distilled water.

Dextran T-70
0.025g
Norit A, neutral
0.250g
Dissolve in lOOml ~f
assay buffer solution.

Table 2
Antiserum Titer Determination
Dilution of Antiserum

Assay
Tubes

Buffe:r: .:1{'!~

Assay Tracer

Undiluted

1:1

1:3

~'"". ·

1,2

1.0 ml

0.1 ml

3,4

0.1 ml

0.1 ml

5,6

0.1 ml

0.1 ml

--

7,8

0.1 ml

0.1 ml

--

O.lml
O.lml

--

O.lml

ij~~
J;;\

t~

rv
l..O
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scintillation cocktail.

The vials were capped tightly,

vortexed and counted for tritium for ten minutes each.
The percent radioactivity bound in tubes 3 through 8
was then determined by reference to the average cpms of
tubes 1 and 2.

By plotting the dilution of antiserum ver-

sus the percent radioactivity bound (Figure 3), the proper
dilution to obtain 40-50% binding was determined.

The re-

mainder of the original concentrate, and other vials of
lyophilized antiserum with the same lot number, were di.luted to the appropriate volume.

The reconstituted anti-

serum was stored at 4°C and mixed well prior to use in
each assay.

In this form the antiserum is stable for ap-

proximately two months.

Indications of deterioration are

a sharp drop in binding from previous levels or a signif icant change in the sensitivity of the standard curve
(McArthur, 1970 and NEN, 1975).
The tritium labeled tracer was supplied in a benzeneethanol (9:1) mixture at a specific activity of 305-450
DPM/pg, or l.5uCi/ml, or approximately lOOOcpm/ul.
recovery

tracer ~as

The

prepared by drying down an appropriate

-

'

aliquot of the tracer ·in a glass vial and redissolving it
in assay buffer to obtain 700-lOOOcpm/0.lml.

The assay

tracer was prepared in a similar manner to obtain approximately 4000cpm/O.lml for the testosterone assay and 5000
cpm/O.lml for the estrogen assay.
The concentrated and diluted tracers were stored
tightly capped at 4°C.

This labeled antigen is stable for
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at least two months under these conditions.

Indications of

deterioration are decreased binding, decreased recovery, or
an increase in the RIA blank (nonspecific binding)

(NEN,

1975).
Stock solutions of testosterone and estradiol were supplied in assay buffer at a concentration of lOOng/ml.

This

material is stable for at least three months when stored
at 4°C.

A standard curve must be run with each assay to

cover the range of concentrations anticipated in the unknowns.

A series of standards were prepared from the stock

solution by diluting O.lml of stock to l.Oml with assay
buffer to obtain a concentration of lng/O.lml.

This was

labeled solution A and further dilutions were made up, as
outlined in Table 3, to provide a range of standards appr6priate for the assays.
The extraction of the artificially prepared bloodstains were carried out in labeled 13Xl00rnrn disposable test
tubes.

From the twelve 2X2cm squares for each individual

one was extracted for the testosterone assay and three were
extracted for

th~~ estrogen
't.f

assay due to the nearly three-

fold differences in plasma concentration (NEN, 1975).
remaining pieces were used in the age study assays.

The
Prior

to each extraction, O.lml of the appropriate recovery
tracer was added to the pieces of cloth in the tubes and
allowed to dry.

The stains were then extracted with 2,2

and lml portions of an organic solvent.

Initially, methyl-

ene chloride was used for the testosterone extraction and
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Table 3

Standard Solutions

Solution

Aliquot (ml)

Assay
Buffer (ml)

Concentration
(ng/0.1 ml)

A

0.1 stock

0.9

1. 00

B

0.5 A

0.5

0.50

c

0.6 B

0.4

0.30

D

0.6

c

0.3

0.20

E

0.5

D

0.5

0.10

F

0.5

E

0.5

0.05

G

0.6 F

0.4

0.03

H

0.6 G

0.3

0.02

I

0.3

0.3

0.01

J

0.3 I

0.3

0.005

H
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di~thyl

ether for the estrogen extracti6n.

However, the

recovery with diethyl ether was greater than recovery with
methylene chloride, so all future extractions were carried
out using diethyl ether.
pooled for each
tubes.

s~mple

The extract portions were then

into corresponding 13Xl00mm test

The organic solvent was then taken to dryness ei-

ther in a vortex evaporator at 37°C under vacuum or by a
stream of nitrogen gas.

Two mls of absolute ethanol was

then added to each tube and they were vortexed for complete dissolution.
The reconstituted samples were then divided into aliquots for use in the recovery determinations and the RIAs.
A O.Sml aliquot was transferred to and dried down directly
in scintillation vials.

Ten mls of Hydromix

1

scintilla-

tion cocktail and O.lml of the appropriate buffer were then
added, the vials were capped, vortexed and counted for ten
minutes each.

The cpms obtained for each were compared

with the average cpms for two vials which contained O.lml
of the recovery tracer and lOml of scintillation cocktail,
the total recove.;,o / standard, to determine the perc"; ,nt of
steroid recovery.
The actual assays were carried out in 12X75mm disposable t e st tub e s

(RIA tub e s) .

Each sampl e wa s prepar ed in

duplicate by transferring two aliquots to labeled duplicate
1

Aquassure scintillation cocktail was used when Hydromix
was unavailable. Aquassure is a trademark of the New England
Nuclear Corporation, Boston, Mass. 02118.

J4

RIA tubes.
nitrogen.

These samples were dried down by a stream of
Total count, blank, zero standard, steroid stan-

<lards and the sample tubes were then prepared as outlined
in Table 4.
18-20 hours.

The incubation of all tubes at 4°C lasted for
Following incubation the tubes were placed

in an ice bath and the proper amount of the appropriate
dextran coated charcoal solution was added to only as many
tubes as could be centrifuged at one time.

The charcoal

solution is not added to any of the total count tubes. After a five minute period, on ice, these tubes were centrifuged at 4°C for 30 minutes at 2700rpm in a bucket-type
centrifuge.

Upon completion of centrifugation equal por-

tions of supernatant from each tube were placed in labeled
scintillation vials containinq lOmls of Hydromix 1 scintillation cocktail.

The vials were tightly capped, vortexed

and counted for tritium for 10 minutes each.
A total of fourteen separate assays were conducted using this procedure.

Three testosterone and three estrogen

assays were performed in each of the open and single blind
studies at 2, 30 and 60 days after the preparation of the
~

bloodstained samples.

Two assays were conducted to test

the cross-reactivity of certain synthetic steroids with the
testosterone and estradiol antiserums.
After the completion of both the open and single-blind
studies the cross-reactivity study, concerning the synthetic
1

Aquassure scintillationcocktail was used when Hydromix
was unavailable. Aquassure is a trademark of the New England
Nuclear Corporation, Boston, Mass. 02118.

Table 4

RIA PROTOCOL

Tube

1

Assay
Buffer (ml)
~·f
.to; r

·~

E

Standard or
Sample (ml)
T
E

Assay
2
Tracer (ml)
Both

Antiserum 3
(ml)
T
E

"' . ,

Charcoal
Suspension
T
E

Total Amount

1. 0

1.20

--

--

0.1

Blank

0.2

0.15

--

--

0.1

--

--

0.8

1.0

Zero Std.

0.1

0.10

--

--

0.1

0.1

0.05

0. 8

1.0

0.1

0.1

0.1

0.1

0.05

0.8

1.0

0.1

0.1

0.05

0.8

1.0

All Stds. 4
All Samples
1

-0.1

-0 .10

(0.5) 5 (0.6) 5

All tubes run in duplicate.

2

The assay tracers were prepared at 4000 cpms for the open and single-blind studies and at 10 4 cpms for the cross-reactivity study.
3
Antiserum is added last in every case. All tubes were incubated at 4°C for approximately 24 hours.
4
standards B-J f{om Table 3 were used in all three studies. The concentrations of
synthetic steroi1 '<. ;!~ shown in Tables 5 and 6 were treated as standards in the crossreactivity study.
5
nried down aliquots of the ethanol reconstituted extracts.

w
\.;,

steroids mentioned previously, was undertaken.

The six syn-

thetic steroids supplied to us, through the various pharmaceutical companies mentioned, were each weighed to the nearest O.Olmg.

Each was dissolved in an appropriate volume

of a benzene:ethanol (9:1) solution to obtain a concentration of lmg/ml.

These stock solutions were appropriately

labeled and serially diluted as outlined in Tables 5 and 6
to give ranges of concentrations which would be suitable
for use in the crbss-reactivity studies.
The determination of the cross-reactivity of these synthetic steroids was accomplished in two separate assays with
the testosterone and estradiol antiserums.

Each of the six

steroids, in the concentration ranges shown in Table 5, were
tested against the estradiol antiserum.

The assay of these

compounds were run concurrently with a set of estradiol
standards prepared as shown in Table 3.

In the cross-

reactivity studies with the testosterone antiserum, there
was a need to conserve some of the components of the testosterone RIA kit and therefore only three representative synthetic

steroid~~' EE

2 , NET and norgestrel were

te~ted.

The

ranges of concentrations shown in Table 6 were assayed concurrently with a

~et

of testosterone standards (Table 3).

The protocol for the cross-reactivity study is the same as
outlined in Table 4 for the other two studies.
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Table 5
Synthetic Steroid Standards for the
Estradiol Cross-Reactivity Study

Solution

Aliquot (ml)

A

0.1 ml stock

B

1

Concentration
(ng/O .1 ml)

10.0

1000.0

0.5 A

0.5

500.0

c

0.6 B

0.4

300.0

D

0.6

c

0.3

200.0

E

0.5 D

0.5

100.0

F

0.5 E

0.5

50.0

G

0.6 F

0.4

30.0

H

0.6 G

0.3

20.0

I

0.5

H

0.5

10.0

J

0.5

I

0.5

5.0

K

0.6 J

0.4

3.0

L

0.6 K

0.3

2.0

--~.

1

Assay
Buffer (ml)

~

~~

The stock solutions of each of the SlX synthetic
steroids at a concentration of lmg/ml in a benzene:
ethanol ( 9: 1) solution were dried down prior to additi on of assay buffer.

]8

Table 6
Sy nthetic Steroid Standards for
Testosterone Cross-Reactivity Study
Ethinyl Estradiol

Solution

Aliquot (ml)

A

0 . 1 Stock

B

1

Assay
Buffer (ml)

Concentration
(ng/0.1 ml)

0.9

0.50

0.6 A

0.4

0.30

c

0.6 B

0.3

0.20

D

0.5

c

0.5

0.10

E

0.5 D

0.5

0.05

Norethindrone and Norgestrel
2

4.9

20.0

4.925

15.0

0.5 A

0.5

10.0

c

0.5

5.0

0.4 D

0.6

2.0

A

0.1 Stock

B

0.75 Stock

c
D

0.5

E

1 The stock

sol~

~

ion for EE 2 contained 5ng/O.lml as£ay

buffer.
2
Th e stock solutions for NET and Norgestrel contained
lOOOng/O.lml assay buffer.
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IV.

RESULTS

The original data obtained from the various studies
were in terms of counts per minute

(cpm) of radioactivity

as determined in a Packard Tri-Carb Liquid Scintillation
Spectrometer Model 3310.

CPMs for duplicate tubes were

averaged and all counts were corrected for background interference by subtracting the blank values obtained for
the same counting session.

The appropriate net cpms were

then manipulated through the use of the equations shown
in Appendix A to determine:

1.

The fractional recovery

of testosterone (T) or estrogen (E) from the extraction
of the bloodstained samples (Eq. I), 2.

the percent radio-

activity bound in the assay of the standards, samples and
synthetic steroids (Eq. II), and 3. the amount of each
steroid (ng) per bloodstained sample (Eq. III).
Titer determinations were made on three different lots
of antiserum (one T and two E).

Duplicates were averaged,

corrected for background and the percent bound det'.~rmined
by reference of the antiserum containing samples to the
total count samples.

The percent bound was then plotted

against the antiserum dilution to produce the graphs shown
in Figure 3 .

The various lots of antiserum were diluted,

as needed, to those proportions on the proper curves which
produce between 40 and 50% binding.

Fig. 3 Antiserum Dilution Curves
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Fr a ctional recoveries were determined for each sample
assay e d within the open and single-blind studies (Eq. I).
The individual values obtained were used in the determination of the actual amount of T or E present in the original
bloodstained sample (Eq . III).

The average fractional re-

covery and standard error (S.E.) were determined for each
of these assays.
all recovery of

These averages, in Table 7, show the over'I'

andEto be 64.3% and 68.8%, respectively.

The percent of radioactivity bound was determined for
the standards, samples and synthetic steroids in every assay
(Eq. II).

The values for each standard were plotted

against the corresponding log-dose of the steroid (ng) on
semi-logarithmic paper . The resulting standard curves are
displayed in Figures 4-15.

Figures 4-13 correspond to the

age group of the samples assayed in the open and singleblind studies and are labeled accordingly . Figures 8 and 9
were used for both the 60 day old samples of the open study
and the 2 day old samples of the single-blind study since
the assays for these groups were performed concurrently.
The standard curves for the cross-reactivity studies
•

-~

(Fig-

ures 14 and 15) were plotted along with the curves obtained
for the synthetic steroids tested, since each synthetic
s t eroid was t re ated as a standard.
Amounts of T and E in the extract aliquot assay ed for
each sample were determined by interpolation from the
proper standard curve.

These values were adjusted to give
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Table 7
Average Fractional Recovery and Standard Errors
Open Study

Testosterone Extract

Estrogen Extract

0.465 + 0.010*

0.751 + 0.004

0.745 + 0.019

0.727 + 0.006

0.922 + 0.014

0.960 + 0.012

Single-Blind Study
Testosterone Extract

Estrogen Extract

0.757 + 0.018

0.684 + 0.033

0.173 + 0.009

0.274 + 0.013

0.798 + 0.017

0.732 + 0.027

* This extraction was performed using methylene chloride.
All other extractions were performed using diethyl ether.
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Fig. 6 TestOsterone Standard Curve - 30 Day Open Study
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Fig. 8 Testosterone Standard Curve - 60 Day Open Study and 2 Day Single-Blind Study
60

!50

40

a

z

:::>

0

30

m
0~

20

10

0
0

, ',.:,
o.cfo2 0.003

,.

0.005

0.010

0.020 0.030

0.050

0.100

0.200 0.300

0,500

TESTOSTERONE ( ng)

"'"
-...J

Fig. 9 Estradiol Standard Curve - 60 Day Open Study and 2 Day Single-Blind Study
60

~o

40

0

z

=>

0

30

m
0~

20

10

<~ ..

0

0

0.002 . 0.003

o.oo~

0 .010

0.020 0.030

0.0'50

0.100

0 . 200 o.3oo

o.~oo

ESTRADIOL ( ng)
..::..

co

Fig. 10

•

Testosterone Standard Curve - 30 Day Single-Blind Study

60

~o

40

0

z

::>
0

m

30

'(;'?.
20

10

0

o

'

o.ooi : 0.003

o.oo~

0.010

0.020 0.030

o.o~o

TESTOSTERONE ( ng)

0.100

0.200 0.300

o.~oo

.t>.

\0
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the amount of T or E in the original bloodstained sample by
1.

taking into account:

the relative amount of blood-

stained material extracted, 2. the functional recovery of
the sample, 3. the reconstituted volume of the extract, and
4. the amount of that volume used in the assay (Eq. III).
These adjusted values were put into ratio form (T:E) for
the same sample at each age.

The resulting ratios for all

samples at each age group are shown in Tables 8 and 9 from
the open and single-blind studies, respectively.
The T:E ratios from the single-blind study were used
to determine the accuracy of this method to predict the
sexual origin of the bloodstained samples in this study at
each age level.

Since it was known that the numbers of

male and female donors for this study were equal (eight),
the ratios were independently divided into two equal groups
at each age .level.

The higher values were designated as

male and the lower values as female.

These designations

were then compared with the correct sexual origin of each
sample.

It was found that the selections correctly desig-

nated within tha _2, 30 and 60 day age levels were ,;,# '%, 62.5%
.

and 50% correct, respectively.

'"'

A test for significance of

a proportion was used to determine which of the percentages
were significantly different from an expected 50% correct,
since this was a single-blind study.

The percent correct at

the 2 day age level was the only value shown to be significant (z=2, critical z_
leve 1.

05

= +
-1.96) within a 95% confidence
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Table 8
T:E Ratios for Open Study
Age of Bloodstains (days)

Sample #
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

2
34.76
32.67
32.40
38.71
41. 80
79.25
57.08
41. 69
62.45
49.67
27.90
41.70
3.03
3.80
1. 61
1.77
3.07
0.50
0.36
1.10
0.00*
0.00*
0.45
1. 30

30

60

16.14
12.35
12.31
1.94
11. 94
11. 53
12.25
3.41
6.17
9.23
6.15
5.06
1. 05
0.90
1. 95
1.00
0.43
0.58
0.26
0.32
0.89
1.16
1.21
0.98

0.088
0.159
0.224
0.042
0.054
0. 0 62
0.190
0.136
0.281
0.364
0.209
0.233
0.450
0.419
0.545
0.307
0.144
1.183
0.374
0.918
1.567
0. 795
0.378
0.453

detected in these samples.

Sex
M

M
M
M
M
M
M
M
M
M
M
M
F
F
F
F
F
F
F
F
F
F
F
F
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Table 9
T:E Ratios for Single-Blind Study
Age of Bloodstains (days)
Sample #
1
2
3
4
5
6
7
8

9
10
11
12
13
14
15
16

* Testosterone

2
1. 95
2.14
2.23
2.33
4.37
2.29
2.79
3.04
2.45
2.69
1. 40
1. 4 7
0.60
1. 50
3.22
2.67

30
0.18
3.94
3.32
0.67
0.49
1. 24
0.85
0.45
0.51
0.34
0 . 62
0.38
0.71
0.00*
2.19
1.88

60

Sex

0.12
0.09
0.12
0.03
0. 2 0
0.07
0.15
0.16
0.09
0.11
0.15
0.20
0.18
0.57
0.67
0.09

F
.M
M
M
M
F
M
M
F
F
F
F
F
F
M
M

· detected in this sample.
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,.

rurther statistical analysis of the T:E ratios for both
the open and single-blind studies included T-tests for dif~erences

between male and female samples at each age level

and between each a9e level within each sex.

The results of

each T-test are displayed in Tables 12 and 13 (Appendix B) .
Analysis of variance

(ANOVA) , based on a two-way mixed de-

sign, was also performed on the mean T:E ratios
from each study.

(Table 10)

The ANOVA analysis should demonstrate:

1. whether there was a significant difference between male
. and female ratios,

(conditions) , 2. whether there was a sig-

nificant difference between ratios for the same samples at
different age levels

(trials) and 3. whether there was a sig-

nificant interaction between the age of the sample and the
distinction between male and female samples
tions) .

(trials x condi-

The source tables for each ANOVA are contained in

Appendix C (Tables 14 and 15).
The T-test analysis for differences between males and
females showed that there was no significant difference between male and female ratios only at the 60 day age level in
confidence level. _g.Jn the

,,

T-test analysis for differences between age levels several
comparisons shov-.Bd no significant difference at a 95% confidence level .

In the open study there was no significant

difference bet,:ween all age comparisons for female ratios.
In the blind study no significant difference was seen between the 2 and 30 day age levels for male ratios or between
the 30 and 60 day levels for the female ratios.
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Table 10

Mean T:E Ratio Values and Standard Errors
Open Study

Age

(Days)

Males

Females

2

45.01 + 4.29

1.42 + 0.52

30

9.04 + 1.34

0.89 + 0.14

60

0.17 + 0.029

0.63 + 0.12

Single-:- Blind Study
2

2.85 + 0.26
-

1.79 -+ 0.24

30

1. 72 + 0.48

0.50 +- 0.13

60

0.19 + 0.07

0.19 -+ 0.06
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ANOVA of the mean T:E ratios from the open study showed
significant differences

(p=0.05) between males and females

at each age level and also between the same samples at different age levels.

There was also a significant interaction

between these two factors.

For the single-blind study,

ANOVA showed significant differences (p=0.05) between males
and females at each level and also between the same samples
at different age levels; however, no significant interaction
occurred between these two factors.
The results from the cross-reactivity study were
handled in a slightly different manner than the results from
the other two studies.

Instead of comparing the cpms of the

standard and synthetic steroid samples to the total counts,
they were compared to the zero standard counts to indirectly
determine the percent of displacement of labeled antigen
from the antiserum (Eq. II).

The percentages obtained for

each standard and synthetic steroid were then plotted
against the corresponding log-dose of the steroid added (ng)
on semi-logarithmic paper. The curves obtained in the testesterone

cross-r~a~ivity

for testosterone, ethinyl estradiol,

norethindrone and norgestrel are displayed in Figure 14.
The curves obtained in the estradiol cross-reactivity study
for estradiol, ethinyl estradiol, mestranol, norethindrone,
norethynodrel, norgestrel and ethynodiol diacetate are displayed in Figure 15.
The percent of cross-reactivity any compound shows with
an antiserum is determined at 50% displacement of the

l

Fig. 14
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labeled antigen.

The amount of the target antigen needed

to displace 50% of the labeled antigen is divided by the
amount of the compound in question needed to displace the
same amount of labeled antigen.

This value is then multi-

plied by 100 to obtain the percent cross-reactivity at 50%
displacement.
Only one of the synthetic steroids tested showed 50%
displacement at the concentrations tested (Table 11).
Ethinyl estradiol showed a 5.00% cross-reactivity with the
estradiol antiserum.

The other compounds tested showed

less than 0.01% cross-reactivity with either the testosterone or estradiol antisera.

(i

Table 11
Cross-Reactivity of Steroids
Percent Cross-Reactivity at 50% Displacement

Compound
Testosterone*
Dihydrotestosterone*
Estradiol-17a*
Estrone*
Estradiol-17!3*
Estriol*
Ethinyl Estradiol
Mestranol
Norgestrel
Norethindrone
Norethynodrel
Ethynodiol Diacetate

T-Antiserum
100.00
56.00
0.10
0.05
0.05
0.05
NS**
NS**
NS**

E-Antiserum
0.001
100.00
50.00
25.00
5.00
5.00
NS**
NS**
NS**
NS**
NS**

Values for these compounds were taken from the Protocols
supplied with RIA kits.
**
NS- Not significant at the therapeutic level or at
higher levels tested (less than 0.01% cross-reactivity).

2

V.

DISCUSSION

The basic principle underlying this study is the wellestablished endocrinological differences between males and
females in terms of the levels of two particular steroid
hormones--testosterone and estrogen.

Besides the basic dif-

ference in the levels .of these hormones between the sexes,
the levels are affected by age, physical condition and by
certain drugs.
Testosterone is formed in the interstitial cells of the
Leydig region in the male testes.

In females testosterone

is produced as an intermediate in estrogen synthesis and in
the reduction of androstenedione and adrenal corticosteroid.
It is normally secreted by the female ovaries in minute
amounts.

Levels of testosterone are relatively low in male

children and in most females.

Testosterone appears in sig-

nificant quantities in newborn males and in adult males any
time after

pube ~ :t:y.

These levels begin to dwindle in males

after age 40, ana decrease to about one-fifth the peak level
by age 80.
In normal nonpregnant females estrogens are cyclically
secreted by the ovaries, with minute amounts secreted by
the adrenal cortices. During pregnancy tremendous quantities
are also secreted by the placenta, up to fifty times that
secreted by the ovaries during a normal cycle.

In males,
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estrogens are present at about one-fifth the level found in
nonpregnant females.

Estrogen in males is produced during

the reduction of testosterone and may also be produced in
the seminiferous tubules and interstitial cells.

Levels of

estrogens are relatively low in female children and they
begin to ·rise and fall in a cyclic pattern after puberty.
Estrogen levels begin to taper off at menopause

(age 40-50)

and approach zero after menopause.
The experiments in this study were designed to determine the limitations involved in applying the RIA technique
in the forensic sciences for the purpose of identifying the
sexual origin of a bloodstain utilizing the hormone principle.

The experiments were devised to test several aspects

of this application.

Both the open and single-blind exper-

iments tested the capability of commercially available RIA
kits to quantitate testosterone and estrogen in extracts of
prepared bloodstains and determined whether the age of a
bloodstain affects that quantification.

The single-blind

study also allowed a determination to be made on the accuracy of using

ratio as a basis for discriminating

between male and female bloodstains.

The cross-rem:::tivity

study became an essential part of this study because of the
possible presence of synthetic steroids in bloodstains from
a source such as oral contraceptives.

This experiment pro-

vided an indication of the possible interference these
steroids might cause by reacting significantly with the
antiserum used in the RIA techniques.
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The recovery results from each assay showed that steroids are easily recovered from bloodstains when extracted
with diethylether.

The average recovery for both testoster-

one and estrogen was about 70% or better (Table 7).
three assays the recoveries were less than 50%.

In

In the

testosterone assay of the 2 day open study the recovery was
only 46.5%.
chloride.

This extraction was performed using methylene
Both testosterone and estrogen assays of the 30

day single-blind study showed less than 30% recovery for unknown reasons.

In the clinical use of these RIA kits, re-

coveries of less than 40% are considered too low and should
be repeated; however, in this study this was

no~

possible

and the assays were carried out as usual.
Radioimmunoassays of the sample extracts produced data
which indicated that significant amounts of each steroid
are detectable.

These amounts were adjusted accordingly

and put into ratio form, T:E (Tables 8 and 9), for comparisons.

The adjusted levels detected for the samples showed

that testosterone levels

~re

within the ranges reported

for males and females in all but the 60 day
·--~

'I

study ~o~
~

both

experiments where testosterone levels were well below those
ranges.

Estrogen levels were above reported ranges in all

assays on male samples and in three of the six assays on
female samples.

This may be due to a higher degree of

cross-reactivity (total estrogen) in the estrogen RIA than
in the testosterone RIA.

66

Comparisons were made within each experiment using the
ratios to determine whether there was a significant difference between male and female ratios and if there was a significant difference between bloodstains at different age
levels (2, 30 and 60 days), which were prepared from the
same blood source.

Analysis of variance, two-way mixed de-

sign, demonstrated that:
(p

1. there was a significant

0.05) difference between male and female ratios, 2. the

age of a bloodstain influences the amount of steroids detected, and 3. in the open study experiments the age of the
bloodstain affected the ability to distinguish between male
and female ratios.

This interaction of the two major fac-

tors of sex and bloodstain age was not seen in the singleblind study which may be due to another time factor:

the

age of the RIA kits.
T-tests were conducted to determine whether any individual comparisons were not significantly different as indicated by ANOVA.

In male vs. female comparisons only the

60 day single-blind study was not significant, which again
may be due to

t:~ · age

of the RIA kits.

For

compar~sons
~

-

of

samples from the same blood source at different bloodstain
age levels there
nificant.

~re

five comparisons which were not sig-

There was very little consistency between the

open and single-blind studies in terms of the significance
or nonsignificance of a particular comparison.

However, it

was observed that values for female bloodstains showed less
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variations between the three age levels (2, 30 and 60 days)
tested than that seen for the male bloodstain values.
From the ratios obtained in the single-blind study determinations were made at each age level on the accuracy of
predicting the sex of a particular sample.

The accuracy de-

creased as the age of the bloodstain increased with only the
75% accuracy at the 2 day level being significant.

This ac-

curacy may also be affected by the age of the RIA kit.
Clinically the RIA kits have a useful life of 3-4
months.

The time involved in completing all assays in this

study required approximately 6 months.

Therefore, the as-

says in the single-blind study were accomplished during the
outer limits of the RIA kits' clinical life.

This could

explain the dramatic differences seen between ratios from
the two experiments.

In the open study the ratios at the

2-day level are much higher than those from the 2 day singleblind study.

However, the ratios from the 2 day single-

blind study were between those from the 30 and 60 day open
study ratios.
seen in the

A supporting fact for this time factor may be
prepared for each ass a ~ ~

An in-

*

di cation of deterioration is a shift in the standa~ d curve
to the right.

This shift is seen to a slight extent when

comparing the standard curves

(Figs. 4-13). Another factor

which would affect these values was the dilution of the antiserum. For most cases the dilution should produce between
40-50% binding but, this was not the case in all assays.
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In imrnunoassays the rule is that the more dilute the antiserum the more sensitive the assay.

Therefore, when the

dilution produced greater than 50% binding the assay was
less sensitive than if the dilution showed 40% binding.
The cross-reactivity experiment showed that there is
very little direct interference from synthetic steroids.
Only ethynyl estradiol showed any significant crossreactivity with the estradiol antiserum.

However, these

steroids may have significant indirect effects, since they
have been shown to decrease the total endogenous estrogen
while they cause slight increases in testosterone.

This be-

comes important in women who are taking oral contraceptive
preparations.

In the open study care was taken to take

blood samples from women who were not taking these preparations.

However, in the single-blind study the female donors

were not selected on this basis and it was not known whether
or not any of thes_e subjects were taking such medication.
This rnay also have affected the female ratios to some extent, in the single-blind study.
are decreased

w~le

If the estrogen levels

testosterone levels are

increqs~d

a fe-

male sample may have been identified as male due to an elevated T:E ratio.
A study of this kind attempts to open a new line of
identification to the forensic serologist.

Although there

are several markers which are readily identified there is
a great need for detection of other markers which further

() <)

id e ntify the individual from whom a bloodstain originat'ed.
With the development of specific antisera the identification
of several genetic markers is easily accomplished.

This

principle can also be applied to physiological factors which
vary as a result of genetic programming.

To this end this

initial investigation was devised to apply such techniques,
through RIA methodology, for determining the sexual origin
of a bloodstain based on the amounts of testosterone and
estrogens detected.
The limitations of this particular study lie in the
time factors involved.

The effects of age in terms of the

age of the bloodstain, the age of the person from whom the
blood sample was obtained and the age of the RIA kits utilized, have been discussed.

The first two are beyond the

control of the investigator and the third must be carefully
monitored in order to have consistence between investigations.

It is recommended that future studies utilize

larger numbers of subjects as blood sources and that the
subjects be screened as to whether they are taking specific
medication,
with the RIAS .

which
In this way a true indication could be made

as to the accuracy of this method in both the presence and
absence of interfering substances .

It is hoped that this

study will contribute to making this p r ocedure as common in
the forensic laboratory as are the procedures for identifying the components of the ABO system.

70

VI.

SUMMARY AND CONCLUSIONS

An investigation -wasmade concerning the ability of commercially available RIA kits to quantify testosterone and
estrogens in extracts of dried bloodstains, for the purpose
of determining the sexual origin of those bloodstains.
Whole blood obtained from male and female volunteers, was
used to prepare twelve bloodstains on pieces of 2 X 2 cm
white cotton linen, for each blood sample.

Bloodstains

were extracted and RIA carried out on the extracts at 2,
30 and 60 days after their initial preparation.

Resulting

·values for testosterone and estrogen from each extract were
put into T:E ratios.

Ratios were compared for male vs. fe-

male differences and also for differences between samples
from the same blood source at the three
age levels.

(2, 30 and 60 days)

The accuracy for discriminating between blood-

stains from male and female sources and the direct interference of several synthetic steroids were also determined
for this appli€~}ijion of the RIA technique.
A significant difference was seen between ratios from
male and female sources in five of the six comparisons.
Only the final comparison, 60 day single-blind assay, showed
no significant difference between male and female bloodstains.

There was also a significant difference between

ratios for bloodstains from the same source at the different
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time intervals (2, 30 and 60 days).

Time was also signifi-

cant in terms of the age of the RIA kits, since there was
an obvious difference between ratios determined for the
bloodstains in the open and single-blind studies.

The ac-

curacy of this method was shown to be 70% or less in the
single-blind study.

Direct interference from the synthetic

steroids was minimal with only one compound, ethynyl estradiol, showing any significant cross-reactivity (5%) with
the estradiol antiserum.
The RIA method then is a potentially useful tool with
applications in the forensic sciences.

For the purpose of

sexual identification the RIA techniques needed are readily
available from commercial sources.
been demonstrated that:

From this study it has

1. the RIA kits are capable of

quantifying the amounts of testosterone and estrogen present
in extracts of bloodstains, 2. the T:E ratio serves as a
fairly accurate basis for discriminating between male and
female samples, and 3. the synthetic steroids tested have
no direct significant effect on the RIA results.
also shown

procedure is subject to

It was

seve ~

limita-

tions, the major one being time in terms of the age of a
bloodstain, and the age of the RIA kit.

A financial limita-

tion arises out of the need to use fresh kits for sensitivity
and accuracy in this method, since sensitivity decreases as
the age of a RIA kit increases.
Also one must consider the indirect effects of the synthetic steroids on the RIA results, since endogenous levels

72

of estrogen and testosteron e are affecte d .
ha~

This may also

influenced the accuracy determinations from the

blind study.

single~

Finally, a double - blind study in which medical

information is available might produce more significant
data.

Further investigation of these factors is therefore

warranted.

'1 J

APPENDIX A

Equations

I

Fractional Recovery (FR) :
FR=

II

Net cpm for sample x 4*
Average net cpm for total recovery standards

Percent Radioactivity Bound (% B):
%B= Corrected cpm standard, sample or syntheticXlOO
Corrected total count*~

III

Steroid Concentrations of Samples:
(ng from curve) x 2***

= ng steroid/sample

Fractional .x Aliquot x Sample
Recovery
Assayed
Extracted
ml

*
**

Since one-fourth of the reconstituted extract is counted.
Corrected zdro standard count was used for standard and
synthetic steroid counts in the cross-reactivity study.
*** Since the dri e d extract is reconstituted to 2.0ml with
absolute ethanol .

•

APPENDIX B
Table 12
T-Test Analysis for Sex
Sample Age (days)
2
Open Study
Single-Blind
Study

30

60

df

Critical t.05

6.04

3.83

22

2.074

2.46

0.31*

14

2.145

*Not significant at the 0.05 level.

Table 13
T-Test Analysis for Age
Age Comparisons (days)
2 vs 30
Open Study

Single-Blind
Study

M

8.16

F

1.36*

M

1. 72*

hi",

2 vs 60

JO vs 60

10.45

6.98

1.68*

4.74

*Not significant at the 0.05 level.

critical t.05

11

2.201

7

2.365

1.44*

11.21

3.20

2.71

1.68*

·:,~

p~~·~··1

df

-..J
~

'
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APPENDIX C
Table 14
Analysis of Variance
Source

..

Total
Between Subjects
Conditions (M, F)
Error
Within Subjects
Trials (2,30,60)
Trials X Conds.
Errors

1

Source Table-Open Study

SS

df

21452.16
6167.05
5258.76
908.29
15289.11
6993.04
6541.59
8283.68

71
23
1
22
48
2
2
44

MS

F

P2

5258.76
41.29

127.36

s

3496.52
3270.80
188.27

18.57
17.37

s
s

Table 15
Analysis of Variance 1 Source Table-Single-Blind Study
Source
Total
Between Subjects
Conditions (M, F)
Error
Within Subjects
Trials (2,30,60)
Trials X Conds.
Error

SS

df

68.24
11. 39
6.95
4.44
56.85
36.64
3.52
16.69

15
1
14
30
2
2
26

MS

F

p

2

45

l Two-Way M'ixe d Design
.
(Bruning, 1968).
2
s-Significant at the 0.05 level.
NS-Not significant at the 0.05 level.

6.95
0.32

21.92

s

18.32
1.79
0.64

28.54
2.79

NS

s
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